Opsidio is focused on addressing chronic diseases linked to chronic inflammation, which can lead to serious health issues such as organ fibrosis. The company is dedicated to developing innovative remedies aimed at mitigating the harmful effects of chronic inflammation that affect millions of individuals. Their current research includes a Phase 2 study targeting moderate to severe Atopic Dermatitis in adults, indicating a commitment to advancing treatment options for patients suffering from this condition.

The company’s approach emphasizes the importance of understanding the underlying mechanisms of chronic inflammation to create effective therapeutic solutions. By concentrating on the biological processes that contribute to chronic diseases, Opsidio aims to break the cycle of inflammation and improve patient outcomes. Their work reflects a broader commitment to addressing the complexities of chronic health issues through scientific research and clinical trials.

United States

Opsidio is a biotechnology company that develops novel biologic therapeutics for patients suffering from fibrotic and allergic diseases. They are passionate about developing remedies for the millions of people affected by the damaging effects of chronic inflammation.

Opsidio

Company Details